Anzeige
Mehr »
Samstag, 16.05.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LC2W | ISIN: US29089Q1058 | Ticker-Symbol: ER4
Tradegate
15.05.26 | 11:25
6,960 Euro
+1,83 % +0,125
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EMERGENT BIOSOLUTIONS INC Chart 1 Jahr
5-Tage-Chart
EMERGENT BIOSOLUTIONS INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,8156,86513:04
6,7806,89515.05.

Aktuelle News zur EMERGENT BIOSOLUTIONS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.05.Emergent BioSolutions Q1 2026 slides: revenue tops guidance amid turnaround13
01.05.Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript2
30.04.Emergent BioSolutions Reports First Quarter 2026 Financial Results176First Quarter 2026 Total Revenues of $156.1 millionFirst Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4%First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA...
► Artikel lesen
30.04.Emergent BioSolutions Inc. - S-8, Securities to be offered to employees in employee benefit plans-
30.04.Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox4
EMERGENT BIOSOLUTIONS Aktie jetzt für 0€ handeln
30.04.Emergent BioSolutions Inc. - 8-K, Current Report2
29.04.H.C. Wainwright reiterates Emergent BioSolutions stock rating at buy4
29.04.Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142292GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support...
► Artikel lesen
29.04.Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN Nasal Spray Among Canadians and Help Save Lives2
28.04.Emergent BioSolutions signs $34.5M vaccine manufacturing, distribution deal4
28.04.Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States207Emergent's Canton facility will manufacture drug substance and obtains exclusive distribution rights GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:...
► Artikel lesen
20.04.H.C. Wainwright bestätigt Kaufempfehlung für Emergent BioSolutions nach Refinanzierung6
20.04.H.C. Wainwright reiterates Emergent BioSolutions stock rating on refinancing3
16.04.Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility171GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company has closed on a new credit facility agreement with OrbiMed for a new $150...
► Artikel lesen
16.04.Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 20261
09.04.Emergent BioSolutions wird Lieferant für Naloxon-Programm in British Columbia8
09.04.Emergent BioSolutions Partners with British Columbia to Supply NARCAN Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program9
07.04.Emergent BioSolutions Launches New NARCAN Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness3
26.03.H.C. Wainwright reiterates Emergent BioSolutions stock rating on contract wins4
25.03.Emergent BioSolutions secures $60M contracts6
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1